ITMI911096A1 - Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus - Google Patents

Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Info

Publication number
ITMI911096A1
ITMI911096A1 IT001096A ITMI911096A ITMI911096A1 IT MI911096 A1 ITMI911096 A1 IT MI911096A1 IT 001096 A IT001096 A IT 001096A IT MI911096 A ITMI911096 A IT MI911096A IT MI911096 A1 ITMI911096 A1 IT MI911096A1
Authority
IT
Italy
Prior art keywords
treatment
synthesis compounds
rhinovirus infections
rhinovirus
infections
Prior art date
Application number
IT001096A
Other languages
English (en)
Inventor
Marino Artico
Federico Corelli
Colla Paolo La
Antonello Mai
Maria Elena Marongiu
Silvio Massa
Alessandra Pani
Enzo Tramontano
Original Assignee
Univ Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cagliari filed Critical Univ Cagliari
Priority to ITMI911096A priority Critical patent/IT1247509B/it
Publication of ITMI911096A0 publication Critical patent/ITMI911096A0/it
Priority to EP92106481A priority patent/EP0509469A1/en
Priority to CA002066394A priority patent/CA2066394A1/en
Priority to US07/870,625 priority patent/US5278184A/en
Priority to KR1019920006514A priority patent/KR920019352A/ko
Priority to JP4128324A priority patent/JPH05148226A/ja
Publication of ITMI911096A1 publication Critical patent/ITMI911096A1/it
Application granted granted Critical
Publication of IT1247509B publication Critical patent/IT1247509B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ITMI911096A 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus IT1247509B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
EP92106481A EP0509469A1 (en) 1991-04-19 1992-04-15 Synthetic compounds suitable for the therapy of infections caused by rhinoviruses
CA002066394A CA2066394A1 (en) 1991-04-19 1992-04-16 Synthetic compounds suitable for the therapy of infections caused by rhinoviruses
US07/870,625 US5278184A (en) 1991-04-19 1992-04-17 Synthetic derivatives of pyrrole and pyrrolidine suitable for the therapy of infections caused by rhinoviruses
KR1019920006514A KR920019352A (ko) 1991-04-19 1992-04-18 리노바이러스(Rhinoviruses)에 의한 감염 치료에 적합한 합성 화합물
JP4128324A JPH05148226A (ja) 1991-04-19 1992-04-20 ライノウイルスによりひき起こされる感染の治療に適した新規な合成化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Publications (3)

Publication Number Publication Date
ITMI911096A0 ITMI911096A0 (it) 1991-04-19
ITMI911096A1 true ITMI911096A1 (it) 1992-10-19
IT1247509B IT1247509B (it) 1994-12-17

Family

ID=11359712

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI911096A IT1247509B (it) 1991-04-19 1991-04-19 Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus

Country Status (6)

Country Link
US (1) US5278184A (it)
EP (1) EP0509469A1 (it)
JP (1) JPH05148226A (it)
KR (1) KR920019352A (it)
CA (1) CA2066394A1 (it)
IT (1) IT1247509B (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231212C (zh) 1999-01-22 2005-12-14 依兰制药公司 抑制vla－4介导的白细胞粘着的多环化合物
ES2339738T3 (es) 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. Derivados de acilo los cuales tratan trastornos relacionados con vla-4.
CA2359112A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US6428942B1 (en) * 1999-10-28 2002-08-06 Fujitsu Limited Multilayer circuit structure build up method
CN1329390C (zh) 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6642232B2 (en) 2001-10-10 2003-11-04 Sugen, Inc. 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
NZ567270A (en) * 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2851103A1 (en) * 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
KR20080100271A (ko) * 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
EP2424841A1 (en) * 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Pyridinone antagonists of alpha-4 integrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205078A (en) * 1977-08-03 1980-05-27 Warner-Lambert Company 3-Pyrrolin-2-one derivatives
CA1299176C (en) * 1985-07-02 1992-04-21 Guy Dominic Diana Process for preparing isoxazole and furan derivatives
ZA846525B (en) * 1983-08-29 1985-04-24 Sterling Drug Inc (substituted)phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof
NZ209209A (en) * 1983-08-29 1988-02-12 Sterling Drug Inc Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions
US4861791A (en) * 1983-08-29 1989-08-29 Sterling Drug Inc. Dihydro-oxazolyl substituted-phenyl-aliphatic lower alkyl and their use as antiviral agents
DE3825559A1 (de) * 1988-07-28 1990-02-01 Basf Ag P-hydroxiphenon-derivate und deren anwendung
GB8912303D0 (en) * 1989-05-27 1989-07-12 Pfizer Ltd Therapeutic agents
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
DE4020851A1 (de) * 1990-06-29 1992-01-02 Cassella Ag 2-(aminoalkyl)-pyrrolaldehyde, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
JPH05148226A (ja) 1993-06-15
US5278184A (en) 1994-01-11
ITMI911096A0 (it) 1991-04-19
CA2066394A1 (en) 1992-10-20
IT1247509B (it) 1994-12-17
KR920019352A (ko) 1992-11-19
EP0509469A1 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
ITBO910476A0 (it) -formulazioni farmeceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali.
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
ITMI911096A1 (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
ITPN920087A1 (it) Macchina per il trattamento e la conservazione delle stoviglie.
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
IT1291340B1 (it) Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale
ITMI931181A1 (it) Procedimento per l'ulteriore trattamento di salcicce
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
ITMI910650A0 (it) Busto ortopedico previsto per il trattamento delle scoliosi
ITMI930341A1 (it) Impiego terapeutico del pirrolidon carbossilato di piridossina
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
HUP9801985A3 (en) Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis
ITMI911206A0 (it) Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari
ITMI911048A0 (it) Nuove composizioni farmaceutiche per il trattamento del morbo di parkinson
KR930703003A (ko) 피부질환치료용 제약 조성물
EP0462621A3 (en) Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections
FR2739290B1 (fr) Utilisation de derives d'acides salicylique pour le traitement des vergetures
IT9021757A0 (it) Prodotto per il trattamento delle nefropatie
EP0449427A3 (en) Use of an antihistamine in the treatment of alcohol intoxication
ITMI910223A0 (it) Composizione farmaceutica per il trattamento delle infezioni polmonari
IT9022513A0 (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
ITMI911343A0 (it) Composizioni farmaceutiche per il trattamento di dermatosi
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
UA15909A1 (uk) Засіб лікуваhhя хроhічhих паhкреатитів
IT1282951B1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento dell'insonnia

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960429